Oncology Hematology Care — Cincinnati, Ohio

Public research footprint of Oncology Hematology Care, compiled from the ClinicalTrials.gov public registry.

516

Registered studies

202

Active

Recruiting now

236

Completed

Stopped or withdrawn

Most-studied conditions

Metastatic Bladder Clear Cell (Glycogen-Rich) Urothelial Carcinoma · Stage IV Cutaneous Melanoma AJCC v6 and v7 · Recurrent Ovarian Carcinoma · Relapsed/Refractory Follicular Lymphoma

Recently updated registry entries

NCT02196181 — Testing Two Different Treatment Schedules of Dabrafenib and Trametinib for Skin Cancer… (Active Not Recruiting)
NCT04708418 — A Study Evaluating Whether Pembrolizumab Alone or in Combination With CMP-001 Improves… (Active Not Recruiting)
NCT02224781 — Dabrafenib and Trametinib Followed by Ipilimumab and Nivolumab or Ipilimumab and… (Active Not Recruiting)

7 more recent registry entries at this facility

Enter your work email to view the full list.

I’d also like to receive occasional marketing emails from Eichor for research sites (optional — unsubscribe anytime).

Work at Oncology Hematology Care?

Verify and correct how your facility appears in public registry records — free.

Verify this profile →

Compiled from public registry records (ClinicalTrials.gov) as of August 03, 2026. Counts reflect how this facility appears in registry listings; name variants may exist and are not combined. This page describes public records only and makes no assessment of any facility.